- Record: found
- Abstract: found
- Article: not found
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
M Cugno
1 ,
R Gualtierotti ,
I Possenti ,
S Testa ,
F Tel ,
S Griffini ,
E Grovetti ,
S Tedeschi ,
S Salardi ,
D Cresseri ,
P Messa ,
G Ardissino
Sep 2014
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that blocks complement activity, has been successfully used in aHUS.